Table 2 Antimicrobial susceptibility profiles of enterococcal isolates investigated
Drug | E. faecalis, n = 72 | E. faecium, n = 05 | Others, n = 38 | ||||||
|---|---|---|---|---|---|---|---|---|---|
R (%) | I (%) | S (%) | R (%) | I (%) | S (%) | R (%) | I (%) | S (%) | |
Erythromycin | 54 (72) | 07 (9.7) | 11 (15.3) | 04 (80) | 0 | 01 (20) | 07 (18.4) | 04 (10.5) | 11 (28.9) |
Tetracycline | 50 (69.4) | 0 | 22 (30.6) | 03 (60) | 0 | 02 (40) | 05 (13.2) | 0 | 33 (86.8) |
Ciprofloxacin | 07 (9.7) | 06 (8.3) | 59 (81.9) | 03 (60) | 01 (20) | 01 (20) | x | x | x |
Moxifloxacin | 01 (0.14) | 0 | 71 (98.6) | 0 | 0 | 05 (100) | 04 (10.5) | 04 (10.5) | 30 (78.9) |
Ampicillin | 01 (1.4) | 0 | 71 (98.6) | 0 | 0 | 05 (100) | 02 (5.3) | 0 | 36 (94.7) |
Gentamicin-Syn | 02 (2.8) | 0 | 72 (100) | 0 | 0 | 05 (100) | 01 (2.6) | 0 | 01 (2.6) |
Nitrofurantoin | 0 | 0 | 72 (100) | 01 (20) | 01 (20) | 03 (60) | 01 (2.6) | 03 (7.9) | 34 (89.5) |
Vancomycin | 0 | 0 | 72 (100) | 0 | 0 | 05 (100) | 20 (52.6) | 0 | 18 (47.4) |
Teicoplanin | 0 | 0 | 72 (100) | 0 | 0 | 05 (100) | 03 (7.9) | 0 | 35 (92.1) |
Linezolid | 0 | 0 | 72 (100) | 0 | 0 | 05 (100) | 01 (2.6) | 04 (10.5) | 34 (89.5) |
Daptomycin | 0 | 0 | 64 (88.9) | 0 | 0 | 01 (20) | 0 | 0 | 07 (18.4) |
MDR | NA | NA | NA | NA | NA | NA | |||
vanA | – | – | – | – | – | – | 06 (15.8) | – | – |
vanB | – | – | – | – | – | – | 03 (7.9) | – | – |